Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs JD.Com Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while JD.Com Inc trades at $27.1 (market cap $36.62B). The key difference: JD.Com Inc is far larger — about 2.9× Halozyme Therapeutics Inc. Common Stock's market cap, and JD.Com Inc pays a 3.72% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and JD.Com Inc for 85 Days on average.
| HALO | JD | |
|---|---|---|
Market Cap | $12.58B | $36.62B |
Volume | 2,179,278 | 6,571,477 |
Sector | Health | Consumer Cyclical |
52-Week High | $115.22 | $34.53 |
52-Week Low | $61.63 | $25.19 |
Typical Hold Time | 1 Days | 85 Days |
Enterprise Value | $14.49B | $19.26B |
Dividend Yield | — | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JD.com (JD) trades at $27.09, up 0.22% on the day, with a bullish technical signal despite mixed moving averages. The stock is deeply undervalued with a P/E of 17.9 and P/S of 0.2, supported by strong cash flow and a robust balance sheet with $234 billion in cash. Recent Q2 2026 earnings beat expectations with EPS of $0.93, and the company is progressing on its $2.5 billion acquisition of Ceconomy, pending EU approval (Reuters, 2026-10-02).
The outlook is positive with a consensus price target of $35.86, implying 32% upside, and 70% of analysts rate it a Buy. Risks include revenue declines, regulatory scrutiny from China and the EU, and competitive pressures. The stock's discount to intrinsic value and strong liquidity position offer a compelling opportunity for long-term investors despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
